Table 3.
Comparison of clinical data between the two groups of patients [mean ± SD/M (P25, P75)]
| Patient characteristics | Endometrial carcinoma group (n=140) | Endometrial disease group (n=67) | t/Z | P |
|---|---|---|---|---|
| Age, year | 51.16±7.61 | 51.70±9.00 | 0.445 | 0.657 |
| BMI, kg/m2 | 23.92±2.54 | 23.36±2.60 | 1.475 | 0.142 |
| CA125, U/mL | 33.69 (19.56, 50.21) | 17.55 (11.25, 29.12) | 5.243 | <0.001 |
| CA19-9, U/mL | 22.34 (13.67, 33.64) | 19.56 (6.80, 28.34) | 2.437 | 0.015 |
| HE4, pmol/L | 86.45±34.80 | 52.03±17.95 | 7.589 | <0.001 |
| VEGF, ng/L | 322.61±88.40 | 227.05±76.73 | 7.549 | <0.001 |
| D-dimer, ng/mL | 383.57±151.46 | 284.18±96.26 | 4.893 | <0.001 |
| RBC, 109/L | 3.74 (3.11, 4.76) | 4.26 (3.11, 5.13) | 1.158 | 0.247 |
| MCH, g/L | 128.35±1.72 | 128.63±1.78 | 1.082 | 0.280 |
| MCV, fL | 87.34±1.42 | 87.53±1.06 | 0.971 | 0.332 |
| RDW, fL | 44.58±2.89 | 44.10±3.16 | 1.078 | 0.282 |
| PLT, 109/L | 223.32±66.94 | 225.33±53.89 | 0.214 | 0.831 |
| MPV, fL | 12.25 (11.00, 13.05) | 11.60 (10.70, 12.60) | 2.369 | 0.018 |
| PDW, fL | 13.81±2.13 | 14.28±1.96 | 1.529 | 0.128 |
| WBC, 109/L | 6.53±1.51 | 6.50±1.22 | 0.169 | 0.866 |
| N, 109/L | 4.02±1.32 | 3.20±0.95 | 4.548 | <0.001 |
| L, 109/L | 1.96 (1.54, 2.40) | 1.81 (1.49, 2.19) | 1.469 | 0.142 |
| MON, 109/L | 0.33±0.12 | 0.33±0.10 | 0.315 | 0.753 |
| NLR | 2.04 (1.53, 2.72) | 1.75 (1.28, 2.36) | 2.578 | 0.010 |
| PLR | 109.15 (83.15, 149.35) | 120.63 (94.78, 152.02) | 1.342 | 0.180 |
| MLR | 0.17 (0.11, 0.23) | 0.17 (0.13, 0.24) | 0.619 | 0.536 |
Note: BMI: body mass index; VEGF: vascular endothelial growth factor; HE4: human epididymis secretory protein 4; RBC: red blood cell count; MCH: mean corpuscular hemoglobin content; MCV: mean corpuscular volume; RDW: red blood cell distribution width; PLT: platelet count; MPV: mean platelet volume; PDW: platelet distribution width; WBC: white blood cell count.